Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
Objectives: To develop and validate radiomics nomograms for the pretreatment predictions of overall survival (OS) and time to progression (TTP) in the patients with advanced hepatocellular carcinoma (HCC) treated with apatinib plus transarterial chemoembolization (TACE), and to assess the incremental value of the clinical-radiomics nomograms for estimating individual OS and TTP. Methods: A total of 60 patients with advanced HCC (BCLC stage C) treated with apatinib plus TACE were divided into a training set (n=48) and a validation set (n=12). The predictors identified from the clinical variables and the radiomics signature constructed from the computed tomography images, such as ɑ-fetoprotein level (AFP), formfactor, the grey level co-occurrence matrix, the gray level size zone matrix, and the gray level run-length matrix, were used to build the clinical-radiomics nomograms and the radiomics nomograms for the prediction of OS and TTP. Results: Apatinib plus TACE benefited the patients with advanced HCC, with a 579-day median OS and a 270-day median TTP. The nomograms were built with the radiomics signature and AFP, and achieved favorable prediction efficacy with acceptable calibration curves. Decision curve analyses demonstrated that the clinical-radiomics nomograms outperformed the radiomics nomograms for the predictions of OS and TTP. Conclusions: Apatinib plus TACE may improve OS and prolonged TTP in the patients with advanced HCC. The clinical-radiomics nomograms, a noninvasive pretreatment prediction tool that incorporate radiomics signature and AFP, demonstrated good prediction accuracy for OS and TTP in these patients. These results indicate that the clinical-radiomics nomograms may provide novel insight for precise personalized medicine approaches in the patients with advanced HCC.
['Li|Lingli|L|', 'Kan|Xuefeng|X|', 'Zhao|Yongjun|Y|', 'Liang|Bo|B|', 'Ye|Tianhe|T|', 'Yang|Lian|L|', 'Zheng|Chuansheng|C|']
D000328:Adult D000368:Aged D006528:Carcinoma, Hepatocellular D016461:Chemoembolization, Therapeutic D003131:Combined Modality Therapy D018450:Disease Progression D005260:Female D006801:Humans D007091:Image Processing, Computer-Assisted D053208:Kaplan-Meier Estimate D008099:Liver D008113:Liver Neoplasms D008297:Male D008875:Middle Aged D009367:Neoplasm Staging D049451:Nomograms D011725:Pyridines D012189:Retrospective Studies D018570:Risk Assessment D013997:Time Factors D014057:Tomography, X-Ray Computed D016896:Treatment Outcome D000509:alpha-Fetoproteins
radiomics survival hepatocellular carcinoma nomogram